Safety Study of CTS21166 to Treat Alzheimer Disease

Phase 1 Completed 56 enrolled CoMentis

Treatment

This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers

Evaluation	Drug	Modality	Dose	Route
Subject	CTS21166	Unknown	7.5 mg	Intravenous
Subject	CTS21166	Unknown	22.5 mg	Intravenous
Subject	CTS21166	Unknown	45 mg	Intravenous
Subject	CTS21166	Unknown	90 mg	Intravenous
Subject	CTS21166	Unknown	150 mg	Intravenous
Subject	CTS21166	Unknown	225 mg	Intravenous